A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study

Edward B Garon; Byoung Chul Cho; Alexander Luft; Jorge Alatorre-Alexander; Sarayut Lucien Geater; Dmytro Trukhin; Sang-We Kim; Grygorii Ursol; Maen Hussein; Farah Louise Lim; Cheng-Ta Yang; Luiz Henrique Araujo; Haruhiro Saito; Niels Reinmuth; Milena Kohlmann; Caitlin Lowery; Helen Mann; Solange Peters; Tony S Mok; Melissa L Johnson

doi:10.1016/j.cllc.2024.03.003

A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study

Clin Lung Cancer. 2024 May;25(3):266-273.e5. doi: 10.1016/j.cllc.2024.03.003. Epub 2024 Mar 15.

Authors

Edward B Garon¹, Byoung Chul Cho², Alexander Luft³, Jorge Alatorre-Alexander⁴, Sarayut Lucien Geater⁵, Dmytro Trukhin⁶, Sang-We Kim⁷, Grygorii Ursol⁸, Maen Hussein⁹, Farah Louise Lim¹⁰, Cheng-Ta Yang¹¹, Luiz Henrique Araujo¹², Haruhiro Saito¹³, Niels Reinmuth¹⁴, Milena Kohlmann¹⁵, Caitlin Lowery¹⁵, Helen Mann¹⁶, Solange Peters¹⁷, Tony S Mok¹⁸, Melissa L Johnson¹⁹

Affiliations

¹ David Geffen School of Medicine at UCLA, Los Angeles, CA. Electronic address: egaron@mednet.ucla.edu.
² Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea.
³ Leningrad Regional Clinical Hospital, St Petersburg, Russia.
⁴ Health Pharma Professional Research, Mexico City, Mexico.
⁵ Prince of Songkla University, Songkhla, Thailand.
⁶ Odessa Regional Oncological Dispensary, Odessa, Ukraine.
⁷ Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
⁸ Acinus, Kropyvnytskyi, Ukraine.
⁹ Florida Cancer Specialists - Sarah Cannon Research Institute, Leesburg, FL.
¹⁰ Queen Mary University of London, London, United Kingdom.
¹¹ Chang Gung Memorial Hospital, Taoyuan City, Taiwan.
¹² Instituto Nacional de Cancer-INCA, Rio de Janeiro, Brazil.
¹³ Kanagawa Cancer Center, Yokohama, Japan.
¹⁴ Asklepios Lung Clinic, Member of the German Center for Lung Research (DZL), Munich-Gauting, Germany.
¹⁵ AstraZeneca, Gaithersburg, MD.
¹⁶ AstraZeneca, Cambridge, United Kingdom.
¹⁷ Centre Hospitalier Universitaire Vaudois, Lausanne University, Lausanne, Switzerland.
¹⁸ Chinese University of Hong Kong, Hong Kong, China.
¹⁹ Sarah Cannon Research Institute, Tennessee Oncology, PLLC, Nashville, TN.

PMID: 38584069
DOI: 10.1016/j.cllc.2024.03.003

No abstract available

Keywords: Clinical trial; Cytotoxic T-lymphocyte-associated antigen 4; Immune checkpoint inhibitor; Immunotherapy; Programmed cell death ligand-1.

Publication types

Clinical Trial, Phase III

MeSH terms

Antibodies, Monoclonal* / administration & dosage
Antibodies, Monoclonal* / therapeutic use
Antibodies, Monoclonal, Humanized* / administration & dosage
Antibodies, Monoclonal, Humanized* / therapeutic use
Antineoplastic Combined Chemotherapy Protocols* / therapeutic use
B7-H1 Antigen* / antagonists & inhibitors
B7-H1 Antigen* / metabolism
Carcinoma, Non-Small-Cell Lung* / drug therapy
Carcinoma, Non-Small-Cell Lung* / pathology
Female
Humans
Lung Neoplasms* / drug therapy
Lung Neoplasms* / pathology
Male
Treatment Outcome

Substances

durvalumab
tremelimumab
CD274 protein, human